Rubric Capital Management LP Aerie Pharmaceuticals Inc Transaction History

Rubric Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $6.1 Million - $11.3 Million	1,231,483 New	1,231,483 $9.24 Million
Q2 2021 Aug 13, 2021	SELL	$15.16 - $18.97 $7.28 Million - $9.11 Million	-480,402 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$13.12 - $20.9 $6.3 Million - $10 Million	480,402 New	480,402 $8.59 Million
Q2 2019 Aug 13, 2019	SELL	$28.97 - $48.21 $4.75 Million - $7.91 Million	-164,070 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$36.32 - $49.25 $14.5 Million - $19.6 Million	-398,115 Reduced 70.82%	164,070 $7.79 Million
Q4 2018 Feb 13, 2019	BUY	$33.0 - $60.04 $18.6 Million - $33.8 Million	562,185 New	562,185 $20.3 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.